$TARS News
Last published 6d ago
- 6d agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to attend the following upcoming investor conferences: Guggenheim 3rd Annual
- 6d agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the...
- 1w agoTARSTarsus Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTARSTarsus Reports Third Quarter 2026 Financial ResultsGlobeNewswireGenerated record XDEMVY® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product
- 1w agoTARSTarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026GlobeNewswireIRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its
- 2w agoTARSTarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerGlobeNewswireIRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has
- 4w agoLSTATARSACHVLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsGlobeNewswireLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors,
- 2mo agoTARSTarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye CareGlobeNewswireAdds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy
- 2mo agoTARSAlkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt DiseaseGlobeNewswireDaily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group.Gildeuretinol was well
- 2mo agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual
- 2mo agoTARSAlkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt DiseaseGlobeNewswireCAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that the
- 3mo agoTARSTarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of GrowthGlobeNewswireGenerated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million Pending acquisition
- 3mo agoTARSTarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity FinancingGlobeNewswireIRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) ("Tarsus") today announced that it has entered into a securities purchase agreement with certain qualified
- 3mo agoTARSTarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership PositionGlobeNewswireAdds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited
- 3mo agoTARSTarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026GlobeNewswireIRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its
- 4mo agoTARSTarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of GrowthGlobeNewswireIRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief
- 4mo agoTARSTarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101GlobeNewswireIRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and
- 5mo agoACHVMANETARSAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 5mo agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 46th
- 6mo agoTARSTarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million AmericansGlobeNewswireCena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around the eyelashesThis common and often overlooked condition is characterized by
- 6mo agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: Bank of America
- 6mo agoTARSTarsus Reports First Quarter 2026 Financial Results and Recent Business AchievementsGlobeNewswireGenerated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak
- 6mo agoTARSTarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026GlobeNewswireIRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its
- 7mo agoTARSTarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme DiseaseGlobeNewswire– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc.
- 7mo agoTARSTP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusGlobeNewswireIRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03
- 8mo agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46th Annual
- 8mo agoTARSTarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business AchievementsGlobeNewswireGenerated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending
- 8mo agoTARSTarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of DirectorsGlobeNewswireIRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and
- 8mo agoTARSTarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026GlobeNewswireIRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its
- 11mo agoTARSTarsus to Participate in Upcoming Investor ConferenceGlobeNewswireIRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on Monday,
- 1y agoTARSTarsus to Participate in Upcoming Investor ConferenceGlobeNewswireIRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation
- 1y agoTARSTarsus Reports Third Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewswireDelivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial
- 1y agoTARSTarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewswireIRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its
- 1y agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th
- 1y agoTARSTarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTARSTarsus Reports Second Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewswireRecord quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and
- 1y agoARQTMIRMNAMSTARSFrazier Life Sciences Closes Oversubscribed $1.3 Billion Venture FundBusiness WireFrazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative
- 1y agoTARSTarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025GlobeNewswireIRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its
- 1y agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th
- 1y agoTARSTarsus to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America
- 1y agoELANTARSElanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownPR NewswireElanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with...
- 1y agoTARSTarsus Reports First Quarter 2025 Financial Results and Recent Business AchievementsGlobeNewswireGenerated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with
- 1y agoTARSTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025GlobeNewswireIRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its
- 1y agoTARSTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual MeetingGlobeNewswireIRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex
- 1y agoDVAXMRNASNYTARS+4Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow ShareholdersBusiness WireBelieves Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on
- 1y agoTARSTarsus Announces Pricing of Upsized $125.0 Million Public OfferingGlobeNewswireIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (the "Company" or "Tarsus") today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of
- 1y agoTARSTarsus Announces Proposed $100.0 Million Public OfferingGlobeNewswireIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (the "Company" or "Tarsus") today announced the commencement of an underwritten public offering of $100.0 million of shares
- 1y agoTARSTarsus to Participate in Upcoming Investor ConferenceGlobeNewswireIRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare
- 1y agoTARSTarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business AchievementsGlobeNewswireGenerated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first
- 1y agoTARSTarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025GlobeNewswireIRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its